At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
ritlecitinib +2 moredrug
Likely dose
ritlecitinib 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, RANDOMIZED, OPEN-LABEL, CROSS-OVER, SINGLE DOSE STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF PEDIATRIC RITLECITINIB (PF-06651600) CAPSULES AND SPRAY CONGEALED BEADS RELATIVE TO ADULT CAPSULES IN HEALTHY ADULT PARTICIPANTS
In Brief
A Phase 1 clinical trial evaluating ritlecitinib for Healthy Participants. Completed, enrolled 12 participants across 1 site.
Detailed Summary
A phase I, single dose study to test two forms of pediatric ritlecitinib compared to adult ritlecitinib in healthy adults aged 18-55 years old. Approximately 12 adults will participate for approximately 2.5 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedSep 2021
Enrollment StartSep 2021
Primary CompletionNov 2021
TodayJul 2026
First PostedSep 10, 2021
Enrollment StartSep 10, 2021
Primary CompletionNov 19, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.8 years ago
Interventions
ritlecitinibdrug
30 mg intact adult capsule
ritlecitinibdrug
10 mg pediatric capsule
ritlecitinibdrug
30 mg spray congealed beads